326
- Dryden GW. Optimizing the use of biologic therapies in the management of inflammatory
bowel disease. Gastroenterol Hepatol (N Y). 2015;11(12):853–6. - Bhosle MJ, et al. Medication adherence and health care costs associated with biologics in
medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17(5):294–301. - Roda G, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin
Transl Gastroenterol. 2016;7:e135. - Dignass A, et al. The second European evidence-based Consensus on the diagnosis and man-
agement of Crohn’s disease: Current management. J Crohns Colitis. 2010;4(1):28–62. - Steenholdt C, et al. Individualised therapy is more cost-effective than dose intensification in
patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, con-
trolled trial. Gut. 2014;63(6):919–27. - Melmed GY, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody
concentrations, and interpretation of results. Clin Gastroenterol Hepatol. 2016;14(9):1302–9. - Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biolog-
ics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther.
2013;38(10):1188–97. - D'Haens GR, et al. The London position statement of the world congress of gastroenterology
on biological therapy for IBD with the European Crohn’s and Colitis organization: when to
start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol.
2011;106(2):199–212. quiz 213 - Biogen Inc. Prescribing information for TYSABRI. Available from: https://www.tysabri.com/
content/dam/commercial/multiple-sclerosis/tysabri/pat/en_us/pdfs/tysabri_prescribing_infor-
mation.pdf. Accessed Jun 2016. - Takeda Pharmaceuticals America, Inc. Prescribing information for ENTYVIO. Available from:
http://general.takedapharm.com/content/file.aspx?filetypecode=ENTYVIOPI&CountryCod
e=US&LanguageCode=EN&cacheRandomizer=23e6ea09-9d25-4ba4-95b6-63633e943cbb.
Accessed Jun 2016. - Janssen Biotech, Inc. Prescribing information for STELARA. Available from: https://www.
stelarainfo.com/pdf/prescribinginformation.pdf. Accessed Oct 2016. - Kane SV. Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol (N Y).
2011;7(8):544–6. - Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients.
Aliment Pharmacol Ther. 2011;33(1):23–32. - Terdiman JP, et al. American Gastroenterological Association Institute guideline on the
use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and
maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):
1459–63. - Rahier JF, et al. Second European evidence-based consensus on the prevention, diagnosis
and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis.
2014;8(6):443–68. - Nordgaard-Lassen I, et al. Guidelines for screening, prophylaxis and critical information prior
to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59(7):C4480. - Mow WS, et al. High incidence of anergy in inflammatory bowel disease patients lim-
its the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol.
2004;2(4):309–13. - Lopez-Serrano P, Perez-Calle JL, Sanchez-Tembleque MD. Hepatitis B and inflammatory
bowel disease: role of antiviral prophylaxis. World J Gastroenterol. 2013;19(9):1342–8. - Chandar AK, et al. Efficacy and safety of natalizumab and vedolizumab for the manage-
ment of Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis.
2015;21(7):1695–708. - Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopa-
thy. N Engl J Med. 2012;366(20):1870–80. - Colombel JF, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut.
2016;66(5):839–51.
L. Zhu and G.Y. Melmed